Fireside chat with Reid Rubsamen, MD scientist who designed vaccine to combat Marburg, a weaponized Ebola virus

Hosted by Strategic Vaccines
July 28, 2021
10:30 AM - 11:30 AM ET
Webcast

Fireside chat with Reid Rubsamen, MD, a visionary MD scientist who designed a revolutionary targeted killer T-cell vaccine to combat Marburg, a weaponized Ebola virus, for the Department of Defense.

We know America and the planet are in the midst of a Pandemic that has taken the lives of over 600,000 Americans and over 4 million world-wide. It is generally believed this particular coronavirus, SARS-CoV-2, was designed in a lab doing gain of function research on virus created to suppress defeat, which inadvertently escaped. So if you want to know why the current vaccines, based on 20th century antibody platforms, are losing their efficacy because they don’t engage enough T-cells to combat a 21st coronavirus engineered to not be defeated, why 50% of Israeli victims of the Delta variant were vaccinated, as reported by the Wall Street Journal, and why the Lambda variant laying waste to Peru, spreading quickly throughout South America and now Canada, could be more resistant to vaccines than the Delta, Dr. Rubsamen has the answers, and can speak with authority on the following:

  • Dispel fact from fiction on current vaccine technologies
  • Provide an overview of the current state of coronavirus outbreaks in US and globally
  • Strengths and weaknesses of mRNA vaccine platforms
  • Explain why the variants are going to continue and are expected to be more easily spread as well as more lethal
  • Discuss the why recovery from Covid is less than perfect for so many millions of recovered Covid victims and the need for a therapeutic that will arrest the development in someone just testing positive
  • Why is there a better alternative to the current antibody platform based vaccines?
  • Why did big pharma do it this way?

Speakers

  • Reid Rubsamen, M.D.

    Title
    CEO at Strategic Vaccines | CEO and Co-Founder Flow Pharma
    @
    Company
    Strategic Vaccines
    Role
    Speaker

    Reid Rubsamen, MD - (Berkeley, AB Bio Chemistry; Stanford, MD & MS Computer Science; Harvard Mass General, Anesthesiology Residency; MIT, NIH funded fellowship Computer Science; MS Harvard, Healthcare Management; 74 Bio Patents) - twenty years ago, after developing revolutionary inhalation insulin delivery for diabetes, Reid had the foresight to postulate the certainty of a coming pandemic from a new lethal virus. Hence, two decades ago, the visionary Reid Rubsamen, MD formed Flow Pharma Inc, an R & D company, to begin the research ultimately resulting in a revolutionary targeted killer T-cell immunology platform ten years ago to treat cancer and viruses that he believed would not be defeated by 20th century antibody platforms.  

    Specialties:

    -Board Certified Anesthesiologist

    -Digital Signal Processing and Mixed Signal Engineer

    -Additional expertise in pharmaceutical chemistry, novel dosage form development and regulatory affairs leading to 510(k) and IND filings in the US as well as filings for clinical trials in the UK, Australia and the Netherlands

  • E. Henry Schoenberger

    Title
    Senior Advisor to the Chairman
    @
    Company
    Strategic Vaccines
    Role
    Speaker

    E. Henry Schoenberger graduated from Miami University in Oxford, Ohio with a degree in English and Economics. For his last book - How We Got Swindled By Wall Street Godfathers, Greed & Financial Darwinism ~ The 30-War Against The American Dream, David Satterfield former Miami Herald business editor, winner of 2 Pulitzers, furnished the foreword and this endorsement:  With keen intellect and searing wit…How We Got Swindled should be must-reading for every policy maker in Washington and every student of economics and finance.” And sponsored Swindled for a Pulitzer.

    Schoenberger has served in a variety of roles in the financial world. In 1968, was among the earliest financial planners nationally; provided testimony to Senate Finance for TRA 86, at the request of Senate Majority Leader, George Mitchell, Senate Majority leader; specialized in succession planning for individuals and corporate owner, and investment advice for five decades. As owner of an NASD Member Firm broker-dealer, the SEC appointed him to its broker dealer committee to submit all proposed rule changes to for comment. He has specialized in real estate private placements and served as a consultant to national real estate sponsors as well as to small business owners. Concurrently he participated in investment banking – raising equity for venture capital start-ups, and stepped in as the CEO to save a VC Florida distillation company from the original founder, emerging from chapter II with a confirmed plan.

    In 1990, his first book - Invest for Success, How To Avoid Getting Ripped off by Real Estate Partnerships, the Stock Market and Diversification –armed readers with questions to ask to elicit answers no one volunteers, warned about the distinction between financial investment and real investment, and provided the Predictability of Substance Theory as a counter to the Modern Portfolio Theory which preached diversification v material knowledge. Larry D. Hayden, CFP President said: “Invest for Success exposes consumers to the pitfalls of real estate investing. If all investors headed his no-nonsense approach to investing, unethical investment schemes would disappear.”   Booklist said: “It just may be the sanest advice you will ever get.”

    From 5 decades of thinking tax and 25 years of teaching his CPE course to prominent Cleveland professionals - CPAs, Bank Trust Officers and Tax Attorneys - on how to avoid number crunching by analyzing material substance for future predictability, Schoenberger has protected clients from financial self-defeat. As a poet-philosopher and pragmatic objective idealist his bifurcated eclectic point of view combines human needs with economic realities.  

About

Strategic Vaccines

Strategic Vaccines LLC is a public private partnership organized to test, manufacture and deploy FLOVID-20, a targeted T-cell therapeutic/vaccine.